Allergic reactions to COVID-19 vaccines
In 2021 many people in the Netherlands will be vaccinated against COVID-19. The mass vaccination and the new types of vaccines trigger questions about the safety of these vaccines. In this paper we discuss: (1) what reactions are expected from COVID-19 vaccines, (2) what precautions are needed when vaccinating people, and (3) how to act when allergic reactions occur. The COVID-19 vaccines include the first vaccines produced with the mRNA platform. The most frequent adverse reactions are comparable with other vaccines. Allergic reactions to COVID-19 vaccines are rare but can occur. These reactions may be related to excipients in the vaccines, like polyethylene glycol. In case of a possible allergic reaction, a doctor, in consultation with an allergist, can investigate whether vaccination is safe in the future and whether precautions are necessary. Allergic reactions to vaccine components must be recorded completely and unambiguously in the patient file.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:165 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 165(2021) vom: 05. Feb. |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Overgevoeligheidsreacties op covid-19-vaccins |
|---|
| Beteiligte Personen: |
Geersing, Tjerk H [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.03.2021 Date Revised 12.03.2021 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM322090903 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322090903 | ||
| 003 | DE-627 | ||
| 005 | 20231225181308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM322090903 | ||
| 035 | |a (NLM)33651507 | ||
| 035 | |a (PII)D5804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Geersing, Tjerk H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allergic reactions to COVID-19 vaccines |
| 246 | 3 | 3 | |a Overgevoeligheidsreacties op covid-19-vaccins |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2021 | ||
| 500 | |a Date Revised 12.03.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In 2021 many people in the Netherlands will be vaccinated against COVID-19. The mass vaccination and the new types of vaccines trigger questions about the safety of these vaccines. In this paper we discuss: (1) what reactions are expected from COVID-19 vaccines, (2) what precautions are needed when vaccinating people, and (3) how to act when allergic reactions occur. The COVID-19 vaccines include the first vaccines produced with the mRNA platform. The most frequent adverse reactions are comparable with other vaccines. Allergic reactions to COVID-19 vaccines are rare but can occur. These reactions may be related to excipients in the vaccines, like polyethylene glycol. In case of a possible allergic reaction, a doctor, in consultation with an allergist, can investigate whether vaccination is safe in the future and whether precautions are necessary. Allergic reactions to vaccine components must be recorded completely and unambiguously in the patient file | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Tempels-Pavlica, Žana |e verfasserin |4 aut | |
| 700 | 1 | |a Borgsteede, Sander D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 165(2021) vom: 05. Feb. |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:165 |g year:2021 |g day:05 |g month:02 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 165 |j 2021 |b 05 |c 02 | ||